Emergent BioSolutions Inc. Contracts & Agreements

Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan (Filed With SEC on May 29, 2024)

Emergent BioSolutions Inc. Inducement Plan (Filed With SEC on December 11, 2023)

Form of Letter Agreement, dated July 26, 2023 (Filed With SEC on December 11, 2023)

Modification No. 28, effective April 14, 2022, to the CDC BioThrax Procurement Contract (Filed With SEC on August 2, 2022)

Modification No. 29, effective June 16, 2022, to the CDC BioThrax Procurement Contract (Filed With SEC on August 2, 2022)

Modification No. 27, effective March 31, 2022, to the Solicitation/Contract/Order for Commercial Items (the CDC BioThrax Procurement Contract), effective December 8, 2016, from... (Filed With SEC on April 29, 2022)

Consulting Agreement, dated as of March 18, 2022 and effective as of April 1, 2022, by and between Emergent BioSolutions Inc. and Fuad El-Hibri (Filed With SEC on April 29, 2022)

Agreement to Terminate Class A Stockholders Registration Rights Agreement, dated December 9, 2021 by and among Emergent BioSolutions Inc., Intervac, L.L.C. and BioVac, L.L.C (Filed With SEC on February 25, 2022)

Modification No. 26, effective November 1, 2021, to the CDC BioThrax Procurement Contract (Filed With SEC on February 25, 2022)

Modification No. 1 (Filed With SEC on February 25, 2022)

Modification No. 4, effective, July 13, 2021 to the ACAM2000 Contract (Filed With SEC on February 25, 2022)

Modification No. 5, effective, September 29, 2021 to the ACAM2000 Contract (Filed With SEC on February 25, 2022)

Modification No. 6, effective, November 1, 2021 to the ACAM2000 Contract (Filed With SEC on February 25, 2022)

Modification No. 3, effective (Filed With SEC on February 25, 2022)

Modification No. 4, effective (Filed With SEC on February 25, 2022)

Modification No. 8, effective (Filed With SEC on February 25, 2022)

Modification No. 31, effective October 20, 2021, to the BARDA ADM Contract (Filed With SEC on February 25, 2022)

Modification No. 32, effective November 1, 2021, to the BARDA ADM Contract (Filed With SEC on February 25, 2022)

Award/Contract (the BARDA AV7909 Contract), effective September 30, 2016, from the BioMedical Advanced Research and Development Authority to Emergent Product Development... (Filed With SEC on November 5, 2021)

Modification No. 1, effective March 16 2017, to the BARDA AV7909 Contract (Filed With SEC on November 5, 2021)

Modification No. 2, effective August 29, 2018, to the BARDA AV7909 Contract (Filed With SEC on November 5, 2021)

Modification No. 11, effective September 30, 2021, to the BARDA AV7909 Contract (Filed With SEC on November 5, 2021)

Modification No. 24, effective February 2, 2021, to the Solicitation/Contract/Order for Commercial Items, effective December 8, 2016, from the Centers for Disease Control and... (Filed With SEC on November 5, 2021)

Modification No. 25, effective September 29, 2021, to the CDC BioThrax Procurement Contract (Filed With SEC on November 5, 2021)

Modification No. 30, effective September 30, 2021, to the Award/Contract, effective June 15, 2012 (the BARDA ADM Contract), from the BioMedical Advance Research and Development... (Filed With SEC on November 5, 2021)

The CDC BioThrax Procurement Contract, effective December 8, 2016 (Filed With SEC on September 9, 2021)

Modification No. 7, effective December 2, 2020, to the Award/Contract, effective September 30, 2016, from the BioMedical Advanced Research and Development Authority to Emergent... (Filed With SEC on July 30, 2021)

Modification No. 8, effective March 22, 2021, to the BARDA AV7909 Contract (Filed With SEC on July 30, 2021)

Modification No. 9, effective April 21, 2021, to the BARDA AV7909 Contract (Filed With SEC on July 30, 2021)

Modification No. 10, effective June 10, 2021 to the BARDA AV7909 Contract (Filed With SEC on July 30, 2021)

Modification No. 3, effective, April 1, 2021, to the Award/Contract, effective August 30, 2019 (ACAM2000 Contract), from the Assistant Secretary, U.S. Department of Health and... (Filed With SEC on July 30, 2021)

Modification No. 27, effective May 6, 2021, to the Award/Contract, effective June 15, 2012 (the BARDA ADM Contract), from the BioMedical Advance Research and Development Authority... (Filed With SEC on July 30, 2021)

Modification No. 28, effective May 27, 2021, to the BARDA ADM Contract (Filed With SEC on July 30, 2021)

Order for Supplies and Services Between Emergent Manufacturing Operations Baltimore LLC and the BioMedical Advance Research and Development Authority, dated (Filed With SEC on July 30, 2021)

Modification No. 1, effective (Filed With SEC on July 30, 2021)

Modification No. 7, effective May 24, 2021, to Order for Supplies and Services Between Emergent Manufacturing Operations Baltimore LLC and the BioMedical Advance Research and... (Filed With SEC on July 30, 2021)

Change Order No (Filed With SEC on July 30, 2021)

Change Order No. 4 to Work Order #5997-01, effective (Filed With SEC on July 30, 2021)

Change Order No (Filed With SEC on July 30, 2021)

Change Order No. 6 to Work Order #5997-01, effective (Filed With SEC on July 30, 2021)

Change Order No (Filed With SEC on July 30, 2021)

Modification No. 4, effective January 29, 2021, to Order for Supplies and Services Between Emergent Manufacturing Operations Baltimore LLC and the BioMedical Advance Research and... (Filed With SEC on April 30, 2021)

Modification No. 5, effective February 22, 2021, to Task Order 75A50120F33007 (Filed With SEC on April 30, 2021)

Modification No. 6, effective March 24, 2021, to Task Order 75A50120F33007 (Filed With SEC on April 30, 2021)

Amendment No. 1, effective February 25, 2021, to Manufacturing Services Agreement, dated July (Filed With SEC on April 30, 2021)

Amendment No (Filed With SEC on April 30, 2021)

Amendment No. 3, effective November 25, 2020, to AZ MSA (Filed With SEC on April 30, 2021)

Amendment No. 4, effective January 21, 2021, to AZ MSA (Filed With SEC on April 30, 2021)

Description of the Company's Securities (Filed With SEC on February 19, 2021)

Global Form of Restricted Stock Unit Award Agreement (Filed With SEC on February 19, 2021)

Modification No. 2 (Filed With SEC on February 19, 2021)

Modification No. 23, effective September 30, 2020, to the CDC BioThrax Procurement Contract (Filed With SEC on February 19, 2021)

Modification No. 2, effective, October 28, 2020 to the ACAM 2000 Contract (Filed With SEC on February 19, 2021)

Modification No. 2, effective September 18, 2020, to Task Order 75A50120F33007 (Filed With SEC on February 19, 2021)

Modification No. 3, effective October 7, 2020, to Task Order 75A50120F33007 (Filed With SEC on February 19, 2021)

Modification No. 2, effective November 17, 2020, to Task Order 75A50120F33008 (Filed With SEC on February 19, 2021)

Modification No. 26, effective November 2, 2020 to the BARDA ADM Contract (Filed With SEC on February 19, 2021)

Modification No. 6, effective July 13, 2020, to the Award/Contract, effective September 30, 2016, from the BioMedical Advanced Research and Development Authority to Emergent... (Filed With SEC on November 6, 2020)

Modification No. 21, effective June 12, 2020, to the Award/Contract, effective June 15, 2012 (the BARDA ADM Contract), from the BioMedical Advance Research and Development... (Filed With SEC on November 6, 2020)

Modification No. 22, effective June 12, 2020, to the BARDA ADM Contract (Filed With SEC on November 6, 2020)

Modification No. 23, effective July 22, 2020, to the BARDA ADM Contract (Filed With SEC on November 6, 2020)

Modification No. 24, effective August 28, 2020, to the BARDA ADM Contract (Filed With SEC on November 6, 2020)

Modification No. 25, effective September 25, 2020, to the BARDA ADM Contract (Filed With SEC on November 6, 2020)

Modification No. 1, effective August 24, 2020, to task order #75A50120F33007, between Emergent Manufacturing Operations Baltimore LLC and the BioMedical Advance Research and... (Filed With SEC on November 6, 2020)

Order for Supplies and Services Between Emergent Manufacturing Operations Baltimore LLC and the BioMedical Advance Research and Development Authority, dated August 6, 2020, under... (Filed With SEC on November 6, 2020)

Modification No. 1, effective August 24, 2020, to (Filed With SEC on November 6, 2020)

Manufacturing Services Agreement, dated July 26, 2020, by and between Emergent Manufacturing Operations Baltimore, LLC and AstraZeneca Pharmaceuticals LP. (AZ MSA) (Filed With SEC on November 6, 2020)

Manufacturing Product Schedule, dated July 26, 2020 to AZ MSA (Filed With SEC on November 6, 2020)

Work Order to Manufacturing Services Agreement, dated June 10, 2020, between Emergent Manufacturing Operations Baltimore, LLC and AstraZeneca Pharmaceuticals LP (included as part... (Filed With SEC on November 6, 2020)

Amendment No. 1, effective September 30, 2020, to AZ MSA (Filed With SEC on November 6, 2020)

Manufacturing Services Agreement, dated July 2, 2020, by and between Emergent Manufacturing Operations Baltimore, LLC and Janssen Pharmaceuticals, Inc., one of the Janssen... (Filed With SEC on November 6, 2020)

Indenture, dated as of August 7, 2020, by and among the Company, certain subsidiaries of the Company and U.S. Bank National Association, as trustee (Filed With SEC on August 7, 2020)

Purchase Agreement, dated as of August 4, 2020, by and among the Company, the subsidiaries of the Company named therein as guarantors, and Wells Fargo Securities, LLC, as... (Filed With SEC on August 7, 2020)

Second Amendment to Amended and Restated Credit Agreement, dated August 7, 2020 (Filed With SEC on August 7, 2020)

Indenture, dated as of August 7, 2020, by and among the Company, certain subsidiaries of the Company and U.S. Bank National Association, as trustee (Filed With SEC on August 7, 2020)

Purchase Agreement, dated as of August 4, 2020, by and among the Company, the subsidiaries of the Company named therein as guarantors, and Wells Fargo Securities, LLC, as... (Filed With SEC on August 7, 2020)

Second Amendment to Amended and Restated Credit Agreement, dated August 7, 2020 (Filed With SEC on August 7, 2020)

Award/Contract, effective June 15, 2012 (BARDA ADM Contract), from the BioMedical Advance Research and Development Authority to Emergent Manufacturing Operations Baltimore LLC (Filed With SEC on July 31, 2020)

Modification No. 19, effective, May 25, 2020, to the BARDA ADM Contract (Filed With SEC on July 31, 2020)

Modification No. 20, effective, May 26, 2020, to the BARDA ADM Contract (Filed With SEC on July 31, 2020)

Order for Supplies and Services Between Emergent Manufacturing Operations Baltimore LLC and the BioMedical Advance Research and Development Authority, dated May 24, 2020, under... (Filed With SEC on July 31, 2020)

Modification No. 1, effective, May 28, 2020 to the Award/Contract, effective August 30, 2019 (ACAM2000 Contract), from the Assistant Secretary, U.S. Department of Health and Human... (Filed With SEC on July 31, 2020)

Modification #No. 4, effective March 3, 2020, to the Award/Contract, effective September 30, 2016, from the BioMedical Advanced Research and Development Authority to Emergent... (Filed With SEC on May 1, 2020)

Modification #No. 5, effective April 10, 2020, to the BARDA AV7909 Contract (Filed With SEC on May 1, 2020)

Description of the Company's Securities (Filed With SEC on February 25, 2020)

Global Form of Restricted Stock Unit Award Agreement (Filed With SEC on February 25, 2020)

Global Form of Non-Qualified Stock Option Agreement (Filed With SEC on February 25, 2020)

Modification No. 18, effective September 11, 2019, to the CDC BioThrax Procurement Contract (Filed With SEC on February 25, 2020)

Modification No. 19, effective January 6, 2020, to the CDC BioThrax Procurement Contract (Filed With SEC on February 25, 2020)

Modification No. 20, effective January 7, 2020, to the CDC BioThrax Procurement Contract (Filed With SEC on February 25, 2020)

Award/Contract (the BARDA AV7909 Contract), effective September 30, 2016, from the BioMedical Advanced Research and Development Authority to Emergent Product Development... (Filed With SEC on February 25, 2020)

Award/Contract, effective August 30, 2019 (ACAM 2000 Contract), from the Assistant Secretary, U.S. Department of Health and Human Services (ASPR/OPM) to Emergent Product... (Filed With SEC on February 25, 2020)

Modification #3, effective July 30, 2019, to the Award/Contract, effective September 30, 2016, from the BioMedical Advanced Research and Development Authority to Emergent Product... (Filed With SEC on November 7, 2019)

Notice of Award Letter, dated August 30, 2019, from the Department of Health and Human Services to Emergent Product Development Gaithersburg, Inc. awarding Contract 75A50119C00052... (Filed With SEC on November 7, 2019)

Modification No. 17, effective June 13, 2019, to the Solicitation/Contract/Order for Commercial Items, effective December 8, 2016, from the Centers for Disease Control and... (Filed With SEC on August 2, 2019)

First Amendment, dated June 27, 2019, to Amended and Restated Credit Agreement, dated October 15, 2018, by and among Emergent BioSolutions Inc., the lenders party thereto from... (Filed With SEC on August 2, 2019)

Amendment No. 2 to License Agreement, dated as of December 15, 2014, by and between Opiant Pharmaceuticals, Inc. (formerly known as Lightlake Therapeutics Inc.) and Adapt Pharma... (Filed With SEC on May 8, 2019)

Emergent BioSolutions Inc. Form of Director Nonstatutory Stock Option Agreement (Filed With SEC on February 22, 2019)

EMERGENT BIOSOLUTIONS INC. Form of Director Restricted Stock Unit Agreement (Filed With SEC on February 22, 2019)

Emergent BioSolutions Inc. Non-Qualified Stock Option Award Agreement (Filed With SEC on February 22, 2019)

Emergent BioSolutions Inc. Form of Restricted Stock Unit Award Agreement (Filed With SEC on February 22, 2019)

Emergent BioSolutions Inc. Non-Qualified Stock Option Award Agreement Canadian Participant (Filed With SEC on February 22, 2019)

Emergent BioSolutions Inc. Form of Restricted Stock Unit Award Agreement Canadian Participant (Filed With SEC on February 22, 2019)

Emergent BioSolutions Inc. Non-Qualified UK Stock Option Award Agreement UK Participant (Filed With SEC on February 22, 2019)

Emergent BioSolutions Inc. Form of UK Restricted Stock Unit Award Agreement UK Participant (Filed With SEC on February 22, 2019)

Emergent BioSolutions Inc. Non-Qualified Stock Option Award Agreement Swiss Participant (Filed With SEC on February 22, 2019)

Emergent BioSolutions Inc. Form of Restricted Stock Unit Award Agreement Swiss Participant (Filed With SEC on February 22, 2019)

Emergent BioSolutions Inc. Non-Qualified Stock Option Award Agreement Irish Participant (Filed With SEC on February 22, 2019)

Emergent BioSolutions Inc. Form of Restricted Stock Unit Award Agreement Irish Participant (Filed With SEC on February 22, 2019)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on February 22, 2019)

PAGE OF PAGES (Filed With SEC on February 22, 2019)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on February 22, 2019)

Modification No. 13, effective September 21, 2018, to the Solicitation/Contract/Order for Commercial Items, effective December 8, 2016, from the Centers for Disease Control and... (Filed With SEC on November 2, 2018)

Modification No. 2, effective August 29, 2018 to the Award/Contract, effective September 30, 2016, from the BioMedical Advanced Research and Development Authority to Emergent... (Filed With SEC on November 2, 2018)

Merger Agreement, dated August 8, 2018, among Emergent, PaxVax, Merger Sub and the Shareholder Representative (Filed With SEC on October 5, 2018)

Commitment Letter, dated August 28, 2018 (Filed With SEC on August 28, 2018)

Modification No. 9, effective June 6, 2018, to the Solicitation/Contract/Order for Commercial Items, effective December 8, 2016, from the Centers for Disease Control and... (Filed With SEC on August 3, 2018)

Modification No. 10, effective June 18, 2018, to the CDC BioThrax Procurement Contract (Filed With SEC on August 3, 2018)

Modification No. 11, effective June 20, 2018, to the CDC BioThrax Procurement Contract (Filed With SEC on August 3, 2018)

Modification No. 12, effective June 21, 2018, to the CDC BioThrax Procurement Contract (Filed With SEC on August 3, 2018)

Modification No. 7, effective February 26, 2018, to the Solicitation/Contract/Order for Commercial Items, effective December 8, 2016, from the Centers for Disease Control and... (Filed With SEC on May 4, 2018)

Modification No. 8, effective March 6, 2018, to the CDC BioThrax Procurement Contract (Filed With SEC on May 4, 2018)

Form of Director Restricted Stock Unit Agreement (Filed With SEC on February 23, 2018)

Form of Restricted Stock Unit Agreement (Filed With SEC on February 23, 2018)

Form of Restricted Stock Unit Award Agreement (Filed With SEC on February 23, 2018)

Modification No. 1 (Filed With SEC on February 23, 2018)

Modification No. 2 (Filed With SEC on February 23, 2018)

Modification No. 3 (Filed With SEC on February 23, 2018)

Modification No. 4 (Filed With SEC on February 23, 2018)

Modification No. 6 (Filed With SEC on February 23, 2018)

Modification No. 5, effective September 8, 2017, to the Solicitation/Contract/Order for Commercial Items (the "CDC BioThrax Procurement Contract"), effective December 8, 2016,... (Filed With SEC on November 3, 2017)

SIXTH AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on May 5, 2017)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on May 5, 2017)

FIFTH AMENDMENT, LIMITED WAIVER AND CONSENT TO CREDIT AGREEMENT (Filed With SEC on February 28, 2017)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on February 28, 2017)

FOURTH AMENDED AND RESTATED EMERGENT BIOSOLUTIONS INC. 2006 STOCK INCENTIVE PLAN (Filed With SEC on August 5, 2016)

CONSULTING AGREEMENT (Filed With SEC on August 5, 2016)

SEPARATION AND DISTRIBUTION AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF JULY 29, 2016 (Filed With SEC on August 4, 2016)

CONSULTING AGREEMENT (Filed With SEC on February 29, 2016)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on February 29, 2016)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDMENT OF SOLICITATION/MODIFICATION OF... (Filed With SEC on February 29, 2016)

THIRD AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on November 6, 2015)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on November 6, 2015)

SECOND AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on May 12, 2014)

FIRST AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on March 10, 2014)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on March 10, 2014)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on November 8, 2013)

Confidential Materials omitted and filed separately with theSecurities and Exchange Commission. Double asterisks denote omissions. PAGE 2The purpose of this modification is to... (Filed With SEC on August 6, 2013)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions (Filed With SEC on August 6, 2013)

FOURTH AMENDMENT TO LEASE AGREEMENT (Filed With SEC on May 3, 2013)

FIFTH AMENDMENT TO LEASE AGREEMENT (Filed With SEC on May 3, 2013)

Emergent BioSolutions Inc. Form of Director Nonstatutory Stock Option Agreement Granted Under the Second Amended and Restated 2006 Stock Incentive Plan (Filed With SEC on March 8, 2013)

EMERGENT BIOSOLUTIONS INC. Form of Director Restricted Stock Unit Agreement Second Amended and Restated 2006 Stock Incentive Plan (Filed With SEC on March 8, 2013)

Form of Restricted Stock Unit Award (Filed With SEC on March 8, 2013)

Amended and Restated Board Compensation Program for Outside Directors Effective May 19, 2011 (Filed With SEC on March 8, 2013)

SECOND AMENDMENT TO LOAN DOCUMENTS (Filed With SEC on November 1, 2012)

PAGE OF PAGES 12 (Filed With SEC on November 1, 2012)

PAGE OF PAGES 1 3 (Filed With SEC on November 1, 2012)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on August 3, 2012)

FIRST AMENDMENT TO LOAN DOCUMENTS (Filed With SEC on August 3, 2012)

Amendment to Loan Documents (Filed With SEC on August 3, 2012)

Temperature Range (Filed With SEC on May 4, 2012)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on May 4, 2012)

SECOND AMENDMENT TO LEASE AGREEMENT (Filed With SEC on March 9, 2012)

FIRST AMENDMENT TO LEASE AGREEMENT (Filed With SEC on March 9, 2012)

Execution CopyExhibit 10.47 THIRD AMENDMENT TO LEASE AGREEMENT (Filed With SEC on March 9, 2012)

Emergent BioSolutions Inc. Amended and Restated Senior Management Severance Plan (Filed With SEC on December 22, 2011)

Emergent BioSolutions Inc. Senior Management Severance Plan (Filed With SEC on November 14, 2011)

Construction Loan Agreement (Filed With SEC on November 4, 2011)

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK (Filed With SEC on November 4, 2011)

[BALANCE OF PAGE INTENTIONALLY LEFT BLANK SIGNATURE PAGE TO FOLLOW] (Filed With SEC on November 4, 2011)

DEPARTMENT OF HEALTH & HUMAN SERVICES (Filed With SEC on November 4, 2011)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on August 5, 2011)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission.Asterisks denote omissions. WYETH LLC ACTING THROUGH ITS WYETH PHARMACEUTICALS... (Filed With SEC on August 5, 2011)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission.Asterisks denote omissions. (Filed With SEC on August 5, 2011)

CONSULTING SERVICES AGREEMENT (Filed With SEC on August 5, 2011)

CONTENTS (Filed With SEC on August 5, 2011)

SEGRO (WINNERSH) LIMITED (1) EMERGENT PRODUCT DEVELOPMENT UK LIMITED (2) DEED OF SURRENDER relating to Units 545 Winnersh Triangle, Wokingham, Berkshire (Filed With SEC on August 5, 2011)

DATED17 May 2011 (Filed With SEC on August 5, 2011)

Exhibit 10.1 February 17, 2011 Greg SiegristPresidentEast West Resources Corporation12001 Glen RoadPotomac, MD 20854Re:Services Agreement with Emergent BioSolutions Inc.Dear Mr.... (Filed With SEC on May 6, 2011)

SUPPLY AGREEMENT (Filed With SEC on March 11, 2011)

AGREEMENT AND PLAN OF MERGER (Filed With SEC on August 13, 2010)

CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on August 13, 2010)

SUPPORT AGREEMENT (Filed With SEC on August 13, 2010)

Very truly yours, ARCH Venture Fund V, L.P. By: ARCH Venture Partners V, L.P. Its: General Partner By: ARCH Venture Partners V, L.L.C. Its: General Partner By: Name: Its: Managing... (Filed With SEC on August 13, 2010)

CONSULTING AGREEMENT (Filed With SEC on August 6, 2010)

* * * * * (Filed With SEC on August 6, 2010)

Amended and Restated Board Compensation Program for Outside Directors Effective May 20, 2010 (Filed With SEC on August 6, 2010)

CONSULTINGSERVICES AGREEMENT (Filed With SEC on May 6, 2010)

EMERGENTBIOSOLUTIONS INC. Restricted Stock UnitAgreement Amendedand Restated 2006 Stock Incentive Plan (Filed With SEC on March 5, 2010)

ANNUALBONUS PLAN FOR EXECUTIVE OFFICERS EMERGENTBIOSOLUTIONS INC. ADOPTEDFEBRUARY 25, 2010 (Filed With SEC on March 5, 2010)

CONFIDENTIAL MATERIALS OMITTED AND FILED SEPERATLY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISK DENOTE OMISSIONS. Talecris BIOTHERAPEUTICS AMENDMENTNO. 1 to the... (Filed With SEC on March 5, 2010)

Talecris BIOTHERAPEUTICS AMENDMENTNO. 2 to the ProductSupply Agreement (Filed With SEC on March 5, 2010)

CONFIDENTIAL MATERIALS OMITTED AND FILED SEPERATLY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISK DENOTE OMISSIONS. Talecris BIOTHERAPEUTICS AMENDMENTNO. 3 to the... (Filed With SEC on March 5, 2010)

Talecris BIOTHERAPEUTICS AmendmentNo. 4 to ProductSupply Agreement (Filed With SEC on March 5, 2010)

CONFIDENTIAL MATERIALS OMITTED AND FILED SEPERATLY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISK DENOTE OMISSIONS. Talecris BIOTHERAPEUTICS FirstAddendum to ProductSupply... (Filed With SEC on March 5, 2010)

CONSULTINGSERVICES AGREEMENT (Filed With SEC on March 5, 2010)

LOANAGREEMENT (Filed With SEC on March 5, 2010)

PROMISSORYNOTE (TermNote) (Filed With SEC on March 5, 2010)

EMERGENT BIOSOLUTIONS INC. (Filed With SEC on October 30, 2006)

RIGHTS AGREEMENT between EMERGENT BIOSOLUTIONS INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, as Rights Agent Dated , 2006 (Filed With SEC on October 30, 2006)

EMERGENT BIOSOLUTIONS INC. (Filed With SEC on October 30, 2006)

Emergent BioSolutions Inc. (Filed With SEC on October 30, 2006)

CLASS A STOCKHOLDERS REGISTRATION RIGHTS AGREEMENT (Filed With SEC on September 25, 2006)

By: /s/ Fuad El-Hibri Title: CEO By: Title: (Filed With SEC on September 25, 2006)

AMENDED AND RESTATED MARKETING AGREEMENT (Filed With SEC on September 25, 2006)

LEASE AGREEMENT BRANDYWINE RESEARCH LLC Landlord and EMERGENT BIOSOLUTIONS INC. Tenant 2273 Research Boulevard Rockville, Maryland 20850 Dated: June 27, 2006 (Filed With SEC on September 25, 2006)

/s/ Fuad El-Hibri 8/9/06 Fuad El-Hibri Dated (Filed With SEC on September 25, 2006)

SERVICES AGREEMENT (Filed With SEC on September 25, 2006)

Amended and Restated Board Compensation Program (Filed With SEC on September 25, 2006)

Schedule 3.3 (Filed With SEC on September 25, 2006)

PROMISSORY NOTE $8,500,000.00 April 25th, 2006 (Filed With SEC on September 25, 2006)

LOAN AGREEMENT (Filed With SEC on September 25, 2006)

PROMISSORY NOTE (Filed With SEC on September 25, 2006)

PROMISSORY NOTE (Revolving Credit Loan) $5,000,000.00 August 25, 2006 (Filed With SEC on September 25, 2006)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 14, 2006)

EMERGENT BIOSOLUTIONS INC. EMPLOYEE STOCK OPTION PLAN (as amended and restated effective January 26, 2005) (Filed With SEC on August 14, 2006)

EMERGENT BIOSOLUTIONS INC. DIRECTOR STOCK OPTION AGREEMENT (Filed With SEC on August 14, 2006)

INDEMNITY AGREEMENT (Filed With SEC on August 14, 2006)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on August 14, 2006)

FILLING SERVICES AGREEMENT (Filed With SEC on August 14, 2006)

Confidential Materials omitted and filed separately with the Securites and Exchange Commission. Asterisks denote omissions. BT VACCINE LICENSE AGREEMENT (Filed With SEC on August 14, 2006)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on August 14, 2006)

ConfidentialMaterials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on August 14, 2006)

Signed: /s/ Fuad El-Hibri Fuad El-Hibri, Chairman of the Board (Filed With SEC on August 14, 2006)

July 11, 2006 Emergent BioSolutions Inc. 300 Professional Drive, Suite 250 Gaithersburg. MD 20879 ###-###-#### f ###-###-#### www.emergentbiosolutions.comDr. Steven Chatfield 31,... (Filed With SEC on August 14, 2006)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on August 14, 2006)

AMENDED AND RESTATED MARKETING AGREEMENT (Filed With SEC on August 14, 2006)

LEASE (Filed With SEC on August 14, 2006)

DATED 13th December 1996 (Filed With SEC on August 14, 2006)

AMENDED AND RESTATED LOAN AGREEMENT (Filed With SEC on August 14, 2006)

LOAN AND SECURITY AGREEMENT (Filed With SEC on August 14, 2006)

PROMISSORY NOTE $7,000,000.00 October 14, 2004 (Filed With SEC on August 14, 2006)

LOAN AGREEMENT (Filed With SEC on August 14, 2006)

DEED OF TRUST NOTE (Filed With SEC on August 14, 2006)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on August 14, 2006)

LOAN AGREEMENT (Filed With SEC on August 14, 2006)

COUNTY COMMISSIONERS OF FREDERICK COUNTY, EMERGENT BIOLOGICS INC. a n d MERCANTILE POTOMAC BANK BOND PURCHASE AGREEMENT Dated as of March 31, 2005 Frederick County, Maryland Tax... (Filed With SEC on August 14, 2006)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on August 14, 2006)

Category

Industry

Companies

Contracts

Emergent BioSolutions Inc. Contracts & Agreements